Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 61

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 3
Chunk 61
---
 may have the right to terminate the license and require us to assign back to Cardiff ProTides the intellectual property which was assigned to us under this agreement, which would result in our being unable to develop, manufacture and sell products that are covered by the licensed intellectual property or the assigned intellectual property or in a competitor’s gaining access to the licensed intellectual property or the assigned intellectual property.
Risks Related to the Commercialization of Our Product Candidates
 Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
 If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:
 •the timing of our receipt of any marketing approvals;
 •the terms of any approvals and the countries in which approvals are obtained;
 •the efficacy and safety and potential advantages and disadvantages compared to alternative treatments;
 •the prevalence and severity of any side effects associated with our products or with any product that is used in combination with our product;
 •the indications for which our products are approved;
 •adverse publicity about our products or favorable publicity about competing products;
 •the approval of other products for the same indications as our products;
 •our ability to offer our products for sale at competitive prices;
 •the convenience and ease of administration compared to alternative treatments;
 •the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
 •the success of our physician education programs;
 •the strength of our marketing and distribution;
 •the availability of third-party coverage and adequate reimbursement, including patient cost-sharing programs such as copays and deductibles; and
 •any restrictions on the use of our products together with other medications.
 We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
 The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There